WILMINGTON, N.C., Nov. 24 /PRNewswire-FirstCall/ -- aaiPharma Inc.
(Nasdaq: AAII), a science-based specialty pharmaceutical company, announced
that the Company has been added to the Nasdaq Biotechnology Index
(Nasdaq: NBI) effective today, November 24, 2003.
"This listing is a testament to aaiPharma's strong financial position and
continued execution of the Company's science-based specialty pharmaceutical
strategy," said Dr. Philip S. Tabbiner, President and CEO of aaiPharma.
Launched in 1993, the Nasdaq Biotechnology Index contains companies that
are classified according to the FTSE(TM) Global Classification System as
either biotechnology or pharmaceutical. The Nasdaq Biotechnology Index is
calculated under a modified capitalization-weighted methodology. All
securities in the Index are listed on the Nasdaq National Market and meet
minimum requirements, including market value, average daily share volume, and
seasoning as a public company. The Index is ranked on a semi-annual basis in
May and in November, and serves as the basis for the iShares Nasdaq
Biotechnology Index Fund(SM) (IBB).
About aaiPharma
aaiPharma Inc. is a science-based specialty pharmaceutical company with
more than 23 years of drug development experience. Focusing on targeted
therapeutic areas, the Company markets a growing portfolio of established
branded products and applies innovative technologies to increase the
commercial potential of these products. At the same time, aaiPharma's research
and development organization is developing a pipeline of products to position
the Company for near-term and long-term growth in its targeted therapeutic
areas. In addition to developing and marketing its own line of proprietary
pharmaceutical products, aaiPharma continues to be a leader in providing
contract pharmaceutical development services through its AAI Development
Services division. For more information on the Company, please visit us on
the web at http://www.aaipharma.com.
SOURCE aaiPharma Inc.
 back to top
Related links:
http://www.aaipharma.com
CONTACT:
media, Andrea L. Johnston, Vice President,
Corporate Communications, +1-910-254-7340, or investors, James B.
Sloan, Jr., Senior Vice President, Corporate Finance,
+1-910-254-7690, both of aaiPharma Inc.
|
